Skip to main content
Top
Published in: Clinical Oral Investigations 2/2019

01-02-2019 | Original Article

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Authors: Alan Motta do Canto, Barbara Michaela Reis da Silva Marcelino, Juliana Lucena Schussel, Bruna F. Wastner, Laurindo Moacir Sassi, Luciana Corrêa, Ronaldo Rodrigues de Freitas, Bengt Hasséus, Göran Kjeller, Celso Augusto Lemos Junior, Paulo Henrique Braz-Silva

Published in: Clinical Oral Investigations | Issue 2/2019

Login to get access

Abstract

Objective

This study aimed to investigate the presence of BRAF V600E mutation in mandible ameloblastomas by correlating clinical and imaging data on the cases studied.

Methods

Eighty-four cases diagnosed as mandibular ameloblastoma were selected for analysis. The specimens were submitted to immunohistochemistry for detection of BRAF V600E mutated protein. Clinical-pathological data such as age, gender, tumour size, mandibular location, radiographic aspects, histological type and sub-type, and tumour status were collected. The clinical-pathological parameters were categorised and analysed according to BRAF V600E detection.

Results

Of the 84 patients, 78.6% (66 cases) demonstrated positivity for anti-BRAF V600E antibody, whereas 18 were negative (21.4%). The correlation between BRAF expression and variables showed statistical significances for mandibular location (P = 0.0353) and tumour size (P = 0.008), whereas no statistical significance was observed for gender, age, radiographic aspect, histological pattern, histological sub-type and tumour status. Multivariate logistic regression revealed a significant risk for BRAF positivity in tumours with posterior mandibular location (OR = 7.23, P = 0.0451) and size > 4 cm (OR = 7.29, P = 0.0150).

Conclusion

BRAF V600E mutation is common in mandibular ameloblastomas, especially in cases of tumours larger than 4 cm and in the posterior region of the mandible. In addition, this mutation can occur regardless of histological type of the tumour, age, gender, radiographic aspect and tumour status.

Clinical significance

The association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia. The use of BRAF inhibitors for targeted therapy could lead to an establishment of an alternative compared to the resective surgery.
Literature
1.
go back to reference Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232:492–498CrossRef Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232:492–498CrossRef
2.
go back to reference McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, Sunwoo J, Colevas AD, Sirjani D (2016) Ameloblastoma: a clinical review and trends in management. Eur Arch Otorhinolaryngol 273:1649–1661CrossRef McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, Sunwoo J, Colevas AD, Sirjani D (2016) Ameloblastoma: a clinical review and trends in management. Eur Arch Otorhinolaryngol 273:1649–1661CrossRef
3.
go back to reference Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB (2016) BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 122:e5–e7CrossRef Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB (2016) BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 122:e5–e7CrossRef
4.
go back to reference Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20:5517–5526CrossRef Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20:5517–5526CrossRef
5.
go back to reference Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, Qu K, Gong X, Ng T, Jones CD, Varma S, Odegaard JI, Sugiyama T, Koyota S, Rubin BP, Troxell ML, Pelham RJ, Zehnder JL, Beachy PA, Pollack JR, West RB (2014) Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 46:722–725CrossRef Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, Qu K, Gong X, Ng T, Jones CD, Varma S, Odegaard JI, Sugiyama T, Koyota S, Rubin BP, Troxell ML, Pelham RJ, Zehnder JL, Beachy PA, Pollack JR, West RB (2014) Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 46:722–725CrossRef
6.
go back to reference Heikinheimo K, Kurppa KJ, Elenius K (2015) Novel targets for the treatment of ameloblastoma. J Dent Res 94:237–240CrossRef Heikinheimo K, Kurppa KJ, Elenius K (2015) Novel targets for the treatment of ameloblastoma. J Dent Res 94:237–240CrossRef
7.
go back to reference Cantwell-Dorris ER, O’Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 10:385–394CrossRef Cantwell-Dorris ER, O’Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 10:385–394CrossRef
8.
go back to reference Wright JM, Vered M (2017) Update from the 4th edition of the World Health Organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathol 11:68–77CrossRef Wright JM, Vered M (2017) Update from the 4th edition of the World Health Organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathol 11:68–77CrossRef
9.
go back to reference do Canto AM, Rozatto JR, Schussel JL, de Freitas RR, Hasséus B, Braz-Silva PH (2016) Immunohistochemical biomarkers in ameloblastomas. Acta Odontol Scand 74:585–590CrossRef do Canto AM, Rozatto JR, Schussel JL, de Freitas RR, Hasséus B, Braz-Silva PH (2016) Immunohistochemical biomarkers in ameloblastomas. Acta Odontol Scand 74:585–590CrossRef
10.
go back to reference Fregnani ER, Perez DE, Paes de Almeida O, Fonseca FP, Soares FA, Castro-Junior G, Alves FA (2017) BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology 70:473–484CrossRef Fregnani ER, Perez DE, Paes de Almeida O, Fonseca FP, Soares FA, Castro-Junior G, Alves FA (2017) BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology 70:473–484CrossRef
11.
go back to reference Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, Cardoso SV, de Faria PR, Dias FL, Eisenberg AL, Loyola AM, Gomez RS (2015) Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol 36:5649–5653CrossRef Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, Cardoso SV, de Faria PR, Dias FL, Eisenberg AL, Loyola AM, Gomez RS (2015) Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol 36:5649–5653CrossRef
12.
go back to reference Carlson ER, Marx RE (2006) The ameloblastoma: primary, curative surgical management. J Oral Maxillofac Surg 64:484–494CrossRef Carlson ER, Marx RE (2006) The ameloblastoma: primary, curative surgical management. J Oral Maxillofac Surg 64:484–494CrossRef
13.
go back to reference Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW (2014) Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 107:378CrossRef Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW (2014) Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 107:378CrossRef
14.
go back to reference Kennedy WR, Werning JW, Kaye FJ, Mendenhall WM (2016) Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy. Eur Arch Otorhinolaryngol 273:3293–3297CrossRef Kennedy WR, Werning JW, Kaye FJ, Mendenhall WM (2016) Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy. Eur Arch Otorhinolaryngol 273:3293–3297CrossRef
Metadata
Title
Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas
Authors
Alan Motta do Canto
Barbara Michaela Reis da Silva Marcelino
Juliana Lucena Schussel
Bruna F. Wastner
Laurindo Moacir Sassi
Luciana Corrêa
Ronaldo Rodrigues de Freitas
Bengt Hasséus
Göran Kjeller
Celso Augusto Lemos Junior
Paulo Henrique Braz-Silva
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 2/2019
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-018-2494-y

Other articles of this Issue 2/2019

Clinical Oral Investigations 2/2019 Go to the issue